Denali Therapeutics DNLI
NASDAQ DNLI
$18.41 -0.27 (-1.45%)
At close: Oct 23, 2026 · 4:00 PM EDT

Denali Therapeutics (DNLI) Cost of Revenue (2026)

Updated

Denali Therapeutics (DNLI) recorded Cost of Revenue of $93,000 in Q2 2026.

Analysis

Denali Therapeutics (DNLI) Cost of Revenue (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 8.10 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 4.29 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 2.52 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.58 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 4.09 Bn
10 Denali Therapeutics 2.94 Bn -473.14 Mn 3.51 Mn 93,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 93,000.00
API Access

Denali Therapeutics Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=DNLI&period=max&api_key=YOUR_API_KEY